en · de · es · pt
cardarine-notes.peptides6823.com › Info › Background And Research Context — Complete Guide

Background And Research Context — Complete Guide

By Editorial Desk · published 2025-08-28 · last reviewed 2025-09-29 · Info

PPARδ agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-09-29. Anything still debated is marked as such rather than presented as settled.

Background and Research Context

Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.

PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.

Detection, Stability, and Quality

Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.

Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.

Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.

Cardarine at a glance

PropertyValueNotes
CAS Registry Number317318-70-0Unique identifier for the compound.
Chemical classPPARδ agonistSynthetic ligand for peroxisome proliferator-activated receptor delta.
AppearanceWhite to off-white solidTypical form of research-grade material.
SolubilitySoluble in DMSO and ethanolPoorly soluble in water.
Typical storage-20°CRecommended for long-term storage of stock solutions.

Background and Regulatory History

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Related pages on this site

Mechanism and Safety Research

GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.

Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.

Mechanism and Laboratory Detection

Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.

Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.

Identity and Regulatory Status

Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.

Reference notes

Currently, one common method for endotoxin detection is the Limulus amebocyte lysate (LAL) test. This test is based on Dr. Frederik Bang's observation that horseshoe crab blood forms clots when exposed to endotoxins. Amoebocyte extract from horseshoe crab blood is mixed with a sample suspected of endotoxin contamination, and a reaction is observed if endotoxins are present. The FDA has approved four variations of the LAL test: gel-clot, turbidimetric, colorimetric, and chromogenic assay. The differences in these variations refer to the characteristics of the amoebocyte/endtoxin reaction (e.g. gel-clot produces a precipitate and colorimetric changes color). This test is fast (approx. 30 minutes) and highly sensitive (up to 0.001 EU/ml sensitivity). However, because it only detects LPS endotoxins, some pyrogenic materials can be missed. Also, certain conditions (sub-optimal pH conditions or unsuitable cation concentration) can lead to false negatives. Glucans from carbohydrate chromatography matrices can also lead to false positives. Since 2003, a synthetic substitute for the LAL test has been commercially available. This recombinant factor C (rFC) test is based on Limulus clotting factor C, the LPS-sensitive part of LAL. The adoption of this test was slow, which began to change in 2016 when the European Pharmacopoeia listed this test as an accepted bacterial-toxin test.

In the 1924 season, for the first time since their inaugural premiership in 1897, there was no ultimate match to decide the league's champion team – either "Challenge Final" or "Grand Final" – to determine the premiers; instead, the top four clubs after the home-and-away season played a round-robin to determine the premiers. Essendon, having previously defeated both Fitzroy (by 40 points) and South Melbourne (by 33 points), clinched the premiership by means of a 20-point loss to Richmond. With the Tigers having already lost a match to Fitzroy by a substantial margin, the Dons were declared premiers by virtue of their superior percentage, meaning that Essendon again managed to win successive premierships. But the low gates for the finals meant this was never attempted again, resulting in Essendon, with its success in the 1897 finals series, having the unique record of winning the only two premierships without a grand final. Prominent contributors to Essendon's 1924 Premiership success included back pocket Clyde Donaldson, follower Norm Beckton, half-back flanker Roy Laing, follower Charlie May, and rover Charlie Hardy. The 1924 season was not without controversy, however, with rumours of numerous players accepting bribes. Regardless of the accuracy of these allegations, the club's image was tarnished, and the side experienced its lowest period during the decade that followed, with poor results on the field and decreased support off it.

==== Prison overcrowding ==== One consequence of the war on drugs policy has been the overcrowding of American prisons. The policy's approach to prosecuting drug-related crimes led to a surge in incarcerated individuals for nonviolent drug offenses. As a result, many prisons have become overburdened, often operating at capacities far beyond their intended limits. Overcrowding strains the prison system and raises questions about the effectiveness of incarceration as a solution to drug-related issues. Resources that could be allocated to address the root causes of drug abuse, provide rehabilitation and treatment programs, or support communities affected by drug-related issues, are instead used to manage the considerable prison population. Critics argue that focusing solely on incarceration fails to address the underlying social factors contributing to drug abuse and perpetuates a cycle of criminality without offering pathways to recovery and reintegration into society.

Sources: en.wikipedia.org

Reference notes

During the 1990s, Brazil saw a surge of critical and commercial success with films such as O Quatrilho (Fábio Barreto, 1995), O Que É Isso, Companheiro? (Bruno Barreto, 1997) and Central do Brasil (Walter Salles, 1998), all of which were nominated for the Academy Award for Best Foreign Language Film, the latter receiving a Best Actress nomination for Fernanda Montenegro. The 2002 crime film City of God, directed by Fernando Meirelles, was critically acclaimed, scoring 90% on Rotten Tomatoes, being placed in Roger Ebert's Best Films of the Decade list and receiving four Academy Award nominations in 2004, including Best Director. Notable film festivals in Brazil include the São Paulo and Rio de Janeiro International Film Festivals and the Gramado Festival. The film I'm Still Here, directed by Walter Salles, was nominated for Best Actress (Torres) and Best Picture at the 97th Academy Awards, and won Best International Feature Film, becoming the first-ever Brazilian produced film to win an Academy Award. The film The Secret Agent had its world premiere at the main competition of the 2025 Cannes Film Festival on 18 May 2025, where it won the Best Actor prize for Wagner Moura, the Best Director prize for Mendonça and the FIPRESCI Prize. It received further widespread critical acclaim.

Existing underlying explanations for the relationship between ADHD and obesity in children include but are not limited to abnormalities in the hypo-dopaminergic pathway, ADHD creating abnormal eating behaviors which leads to obesity, or impulsivity associated with binge eating leading to ADHD in obese patients. A systematic review of the literature on the relationship between obesity and ADHD concluded that all reviewed studies reported ADHD patients were heavier than expected. However, the same systematic review also claimed that all the evidence supporting this connection was still limited and further research is still necessary to learn more about this connection. Given the prevalence rates of both obesity and ADHD in children, understanding the possible relationship between the two is important for public health, particularly when exploring treatment and management options. Direct intervention for psychological treatment of childhood obesity has become more prevalent in recent years. A meta-analysis of the psychological treatment of obesity in children and adolescents found family-based behavioral treatment (FBT) and parent-only behavior treatment to be the most effective practices in treating obesity in children within a psychological framework.

== Treatment == Once a nickel allergy is detected, the best treatment is avoidance of nickel-releasing items. The top 13 categories that contain nickel include beauty accessories, eyeglasses, money, cigarettes, clothes, kitchen and household, electronics and office equipment, metal utensils, aliment, jewelry, batteries, orthodontic and dental appliances, and medical equipment. Other than strict avoidance of items that release free nickel, there are other treatment options for reduction of exposure. The first step is to limit friction between skin and metallic items. Susceptible people may try to limit sweating while wearing nickel items, to reduce nickel release and thus decrease chances for developing sensitization or allergy. Another option is to shield electronics, metal devices, and tools with fabric, plastic, or acrylic coverings. There are dimethylglyoxime test kits that can be very helpful to check for nickel release from items prior to purchasing. The American Contact Dermatitis Society 'find a provider' resource can help identify clinicians with training in providing guidance lists of safe items. In addition to avoidance, healthcare providers may prescribe additional creams or medications to help relieve the skin reaction.

Sources: en.wikipedia.org

Notes from published material

== Mechanism == A CI experiment involves the use of gas phase acid-base reactions in the chamber. Some common reagent gases include: methane, ammonia, water and isobutane. Inside the ion source, the reagent gas is present in large excess compared to the analyte. Electrons entering the source will mainly ionize the reagent gas because it is in large excess compared to the analyte. The primary reagent ions then undergo secondary ion/molecule reactions (as below) to produce more stable reagent ions which ultimately collide and react with the lower concentration analyte molecules to form product ions. The collisions between reagent ions and analyte molecules occur at close to thermal energies, so that the energy available to fragment the analyte ions is limited to the exothermicity of the ion-molecule reaction. For a proton transfer reaction, this is just the difference in proton affinity between the neutral reagent molecule and the neutral analyte molecule. This results in significantly less fragmentation than does 70 eV electron ionization (EI). The following reactions are possible with methane as the reagent gas.

==== Books ==== In the 1942 short story "Funes the Memorious" by Jorge Luis Borges, the protagonist suffers a head injury after which he gains the ability to remember every detail of what he experiences, but comes to view this as a curse. In the 1980 series The Book of the New Sun by Gene Wolfe, the protagonist remembers everything he has ever seen starting from infancy. He describes his memories as being so vivid that he is capable of re-living anything he has experienced whenever he chooses to do so. In a 2011 manga by Kohske called Gangsta, the main character, Worick Arcangelo, is said to have hyperthymesia, which he uses to help police identify murder victims. In the 2015 novel Memory Man by David Baldacci, the protagonist, Amos Decker, has hyperthymesia. In the book, a mystery-crime scene-thriller with graphic scenes, Decker uses his perfect memory brought on by a traumatic hit in football to solve the murder of his wife and child, and the school shooting connected to it. Decker recalls his memories as a "DVR", just playing when it wants to, or being rewound and played forward by conscious thought. In the 2021 romantic suspense series Memento Mori by C.S. Poe, the protagonist, Everett Larkin, has hyperthymesia. Larkin suffered a traumatic brain injury at the age of 18, leaving him with highly superior autobiographical memory (HSAM) but very poor short-term memory. He remembers events since his injury with perfect recall, and memories are often brought to the surface through "associations." Larkin uses his superior memory as a detective on the NYPD cold case squad.

1993/2568) Portsmouth Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2569) Riverside Community Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2570) Robert Jones and Agnes Hunt Orthopaedic and District Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2571) Rockingham Forest National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2572) Royal Shrewsbury Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2573) Royal Wolverhampton Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2574) Salisbury Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2575) Solihull Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2576) Stoke Mandeville Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2577) Wandsworth Community Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2578) Warwickshire Ambulance Service National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2579) South Warwickshire Mental Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2580) Winchester and Eastleigh Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2581) Worcester Royal Infirmary National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2582) Chichester Priority Care Services National Health Service Trust (Establishment) Order 1993 (S.I.

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine?

Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.

Is cardarine a steroid?

No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.

What did animal studies find?

Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.

How is cardarine measured in biological samples?

LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.

Network